MedTrace Logo

Metronomic Chemotherapy in Advanced Gastric Cancer

NCT02855788 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-08-04

No results posted yet for this study

Summary

phase II study of weekly metronomic chemotherapy using weekly Paclitaxel, Oxaliplatin, Leucovorin and 5-FU (POLF) in patients with advanced gastric cancer

Conditions

  • Metastatic Gastric Cancer
  • Locally Advanced Gastric Cancer

Interventions

DRUG

Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly

metronomic chemotherapy

Sponsors & Collaborators

  • Seattle Integrative Cancer Center

    collaborator UNKNOWN

  • Huashan Hospital

    lead OTHER

Principal Investigators

  • Jie Liu, M.D. · Huashan Hospital

  • Nick N Chen, M.D., Ph.D. · Seattle Integrative Cancer Center

  • Jun Zhang, M.D. · Huashan Hospital

  • Zhongguang Luo, M.D. · Huashan Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2018-07-31
Completion
2018-10-31

Countries

  • United States
  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02855788 on ClinicalTrials.gov